Randomized Conversion Of Epstein-Barr Virus (EBV)+ Kidney Transplant Recipients Of Living Or Standard Criteria Donors At Three Months Post Transplantation To Belatacept With MPA Or Belatacept With Low-Dose Tacrolimus (50% Of Dose) Compared To Patients Remaining On Center Specific Standard Therapy Of Tacrolimus And MPA
Phase of Trial: Phase IV
Latest Information Update: 03 Oct 2018
Price : $35 *
At a glance
- Drugs Belatacept (Primary) ; Mycophenolate mofetil; Mycophenolic acid; Tacrolimus
- Indications Renal transplant rejection
- Focus Adverse reactions
- 21 Sep 2018 Planned End Date changed from 1 Jul 2018 to 1 Jul 2023.
- 21 Sep 2018 Planned primary completion date changed from 1 Jul 2018 to 1 Jul 2022.
- 15 Sep 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Jul 2018.